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To determine the prevalence of porcine circovirus 2 (PCV2) genotypes in the USA during 2010–
2011, 5 years after widespread PCV2 vaccination, serum samples from clinically normal pigs that
were PCV2 vaccinated (n51177), non-vaccinated (n5378) or of unknown vaccination status
(n5120), and 100 lung samples from pigs diagnosed with PCV-associated disease (PCVAD) were
tested. The presence of PCV2, PCV1, PCV1-2a and porcine parvovirus (PPV) DNAwas determined
by PCR. Determination of the PCV2 genotype was done by differential PCR and sequencing. The
prevalence of PCV2a and PCV2b in serum samples was 7.7% (129/1675) and 8.4% (141/1675),
respectively. PCV2a DNA was only detected in non-vaccinated pigs. For the 100 PCVAD pigs, the
prevalence of PCV2a and PCV2b in lung tissues was 13.0 and 65.0%, respectively. Partial PCV2
ORF2 sequences (9–563 nt) were obtained from 85 PCV2 DNA-positive samples (24 normal pigs
and 61 PCVAD cases). Phylogenetic analysis revealed that 12.9% (11/85) of the sequences
belonged to the 2E clade and the PCV2a genotype and 87.1% (74/85) belonged to the 1B clade
and the PCV2b genotype. The alignment of putative PCV2 capsid amino acid sequences revealed
possible recombination or mutation between PCV2a and PCV2b genotypes. Chimeric PCV1-2a
was not detected in any of the samples and the prevalence rates of PCV1 and PPV were low. Our
results suggest PCV2b is more prevalent than PCV2a in PCVAD cases and in vaccinated herds
PCV2b circulation is common. The data generated in this study provide novel information on the
distribution of PCV2 genotypes in vaccinated pig populations.
INTRODUCTION
Porcine circovirus (PCV) is a circular ssDNA virus in the
family Circoviridae (Tischer et al., 1982). Two types of PCV
have been described up to now, PCV type 1 (PCV1) and
PCV type 2 (PCV2). PCV1 was first isolated from a porcine
kidney cell line (PK-15) (Tischer et al., 1974) and was not
pathogenic to pigs (Tischer et al., 1986), whereas PCV2 is
associated with a number of disease manifestations
(porcine circovirus-associated disease, PCVAD) including
post-weaning multisystemic wasting syndrome (PMWS),
porcine respiratory disease complex (PRDC), porcine
dermatitis and nephropathy syndrome (PDNS), pneu-
monia, diarrhoea in grow-finish pigs and reproductive
failure (Opriessnig et al., 2007).
The overall DNA sequence homology within PCV1 or
PCV2 isolates is greater than 90%, while the homology
between PCV1 and PCV2 isolates is 68 to 76% (Hamel et
al., 1998; Larochelle et al., 2002; Meehan et al., 1998; Zhou
et al., 2006). Three ORFs were recognized in PCV2 with
ORF1 located on the viral plus-strand, and ORF2 and
ORF3 on the counterclockwise strand. PCV2 ORF1
encodes a 35.7 kDa replication protein involved in virus
replication (Mankertz et al., 1998). PCV2 ORF2 encodes a
27.8 kDa capsid protein (Cap) involved in viral immuno-
genicity (Nawagitgul et al., 2000). PCV2 ORF3 protein is
not essential for PCV2 replication, but is involved in
PCV2-induced apoptosis (Liu et al., 2005).
A unified nomenclature for PCV2 genotypes (PCV2a,
PCV2b and PCV2c) has been proposed (Segale´s et al.,
2008). PCV2 has two major genotypes: PCV2a (or group
2), which was further subdivided into five clusters (2A–2E),
and PCV2b (or group 1) subdivided into three clusters
(1A–1C) (Olvera et al., 2007). A third genotype (PCV2c)
was identified in Denmark (Dupont et al., 2008). PCV2d
and PCV2e have been proposed to be PCV2 novel
genotypes emerging in China (Wang et al., 2009); however,
they were later demonstrated to belong to the PCV2a and
PCV2b clusters (Cortey et al., 2011). Severe PCVAD
The GenBank/EMBL/DDBJ accession numbers are shown in Table S1
(available in JGV Online).
Supplementary tables are available with the online version of this paper.
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outbreaks emerged in North America during 2005–2006
(Cheung et al., 2007); the main PCV2 subtype isolated
during these outbreaks was found to be PCV2b, which was
different from investigations conducted prior to 2005 that
only identified PCV2a (Cheung et al., 2007; Fenaux et al.,
2000; Larochelle et al., 2002).
PCV2 vaccination was introduced in 2006 in the USA
(Opriessnig et al., 2007). The currently available commer-
cial PCV2 vaccines in North America include an inactiv-
ated vaccine based on a chimeric PCV2, two subunit
vaccines based on the PCV2 Cap expressed in the
baculovirus system, and an inactivated vaccine based on
a PCV2 virus (Opriessnig et al., 2007). Because of the
detection of a novel chimeric PCV2 virus (PCV1-2a)
containing PCV1 ORF1 and PCV2a ORF2 in Canada in
2010 (Gagnon et al., 2010), the chimeric PCV2 vaccine
(Suvaxyn PCV; Fort Dodge Animal Health Inc.) was
voluntarily removed from the market in May 2010 due to
concerns about the inactivation process. A reformulated
version of the chimeric PCV2 vaccine re-entered the
market in August 2011 under a new brand name (Fostera
PCV; Pfizer Animal Health Inc.). All the currently available
vaccines, regardless of the type, are based on PCV2a
isolates (Opriessnig et al., 2007). It is estimated that today
99% of all growing pigs in the USA are vaccinated against
PCV2 at or around the time of weaning.
To the best of our knowledge, an investigation of PCV2
subtype distribution and prevalence of PCV2 in USA herds
after implementation of widespread PCV2 vaccination is
lacking. The objectives of this study were (i) to investigate
the prevalence of PCV2a and PCV2b in serum samples of
grow-finish herds with no known history of PCVAD, and
(ii) to investigate the predominant PCV2 subtype in cases
diagnosed as PCVAD by histopathology. Additionally, the
prevalence of PCV1, PCV1–2a and porcine parvovirus
(PPV) was also investigated.
RESULTS
Prevalence of major PCV2 subtypes
Serum samples. Within the 1675 serum samples, 1177 were
from vaccinated pigs, 378 were from non-vaccinated pigs
and 120 were from pigs with unknown PCV2 vaccination
history. Among the 1675 serum samples, 129 (7.7%)
samples were positive for PCV2a and 141 (8.4%) were
positive for PCV2b DNA (Table 1). PCV2 DNA was not
detected in samples from 45.9% (28) of the 61 sites from
which 33.1% (554 serum samples) of the 1675 serum
samples were received. PCV2a was identified in four sites
and six barns with 2–49 samples positive in each barn
[mean, 21.5; confidence interval (CI), 20.5, 43.5]. PCV2b
was identified on 28 sites in 29 barns with 1–26 samples
being positive in each barn (mean, 4.9; CI, 2.9, 6.9). For
PCV2a, samples derived from non-vaccinated pigs had a
higher prevalence (34.1 versus 0%) than those derived
from vaccinated pigs (Table 2). Interestingly, for PCV2b,
samples from vaccinated pigs had significantly higher viral
DNA loads (0.64±0.06 versus 0.21±0.05 log10 copies
ml21) than those found in non-vaccinated pigs (Table 2).
Site and barn nested within site had no effect on the results
based on vaccination status (vaccinated; non-vaccinated)
for both log10 PCV2a and PCV2b DNA loads.
For the 1177 samples from herds known to utilize PCV2
vaccination, 922 samples were from herds using one of the
three commercial vaccines (Table 3) and 255 samples were
from herds that were vaccinated, but it was not absolutely
clear which of the products had been used on the group of
pigs. When the results were compared based on vaccine
products used, pigs vaccinated with Suvaxyn PCV had
lower PCV2b DNA loads compared with pigs vaccinated
with Ingelvac CiroFLEX and Circumvent PCV (Table 3).
Site and barn nested within site had no effect on the results
and were controlled for in the model. An association of age
and prevalence of PCV2 DNA was not identified (data not
shown).
PCVAD cases. For the PCVAD cases, the prevalence of
PCV2a and PCV2b was 13.0% (13/100) and 65.0% (65/100),
with PCV2 DNA loads of 1.21±0.32 and 6.47±0.52 log10
copies ml21, respectively (Table 1). Specifically, in lung
tissues single PCV2 infection was identified in 10 of 100
cases, single PCV2b infection was identified in 62 of 100
cases, concurrent PCV2a and PCV2b infection was iden-
tified in 3 of 100 cases and PCV2 DNA was not detected in
25 of 100 cases. Comparison of the prevalence and level of
PCV2 DNA load in serum samples revealed the prevalence
of PCV2a and PCV2b was significantly (P,0.05) higher in
tissue samples, and tissue samples had significantly higher
(P,0.05) PCV2a and PCV2b DNA loads (Table 1). When
the amount of PCV2 DNA in PCVAD cases was compared,
no age-related association was identified (data not shown).
The mean number of positive samples on a site was 1–5 pigs.
The PCV2a-positive samples were from 11 sites and the
PCV2b-positive samples were from 54 sites. Site and barn
nested within site had no effect on the results.
PCV2 ORF2 gene sequence analysis
Samples with cycle threshold (Ct) values lower than 32 in
real-time PCR were selected for sequencing. Partial PCV2
ORF2 sequences (9–563 nt) were obtained from 85 PCV2
PCR-positive samples, including 24 serum and 61 PCVAD
cases; the sequence IDs and GenBank accession numbers
are shown in Table S1. Closely related sequences (with
distances of less than 0.005) that differed by up to 3 nt and
one putative amino acid was represented by a single
representative sequence with the numbers of similar
sequences in phylogenetic analysis (Table S2); as a result,
17 representative sequences were identified with distances
of more than or equal to 0.005. A phylogenetic tree was
constructed from the 17 representative sequences, 11 PCV2
reference sequences, as well as one sequence for the PCV1–
2a vaccine (GenBank accession no. AF264042) (Fig. 1). The
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analysis revealed that 11/85 sequences belonged to the
PCV2a genotype and 74/85 belonged to PCV2b (Fig. 1).
In pairwise comparisons, the partial PCV2 ORF2 nucleo-
tide sequences had distances of 0.005–0.022 among the
PCV2a sequences, 0.005–0.028 among the PCV2b se-
quences, and 0.050–0.086 between PCV2a and PCV2b
sequences. For pairwise comparisons of the amino acid
sequences, the distances were 0.005–0.044 within PCV2a,
0.005–0.085 within PCV2b, and 0.073–0.103 between
PCV2a and PCV2b. All the 11 PCV2a nucleotide sequences
belonged to the 2E clade (Fig. 1) with distances of 0.011–
0.016 with the 2E reference strain (GenBank accession no.
AF264039). All the PCV2a samples had distances of 0.016–
0.033 with the PCV1–2a ORF2 nucleotide sequence (data
not shown). All the 74 PCV2b sequences belonged to the
1B clade (Fig. 1). To the prototype of this clade, GenBank
accession no. AY678532, the sequences from the samples
had distances between 0.005 and 0.016.
Putative PCV2 Cap amino acid sequence analysis
In order to investigate the amino acid variation in Cap of
the two major PCV2 genotypes detected in the samples,
185 putative amino acid sequences (positions 4–188) of the
PCV2 Cap obtained in this study were aligned with the 11
known PCV2 clades (1A–1C and 2A–2D) and three known
genotypes (2a, 2b and 2c) and the PCV1–2a vaccine
reference sequence (Fig. 2). Fifty-three of the 74 PCV2b
Cap amino acid sequences were closely related to PCV2
clades 1A and 1B reference strains within the PCV2b
genotype with only one amino acid difference. The
following amino acid substitutions between PCV2a and
PCV2b genotypes were identified: for PCV2b Cap amino
acid sequences, 6/74 varied at position 30 (V to L, same as
2E clade reference strains in PCV2a), 3/74 varied at
position 76 (I to L, same as 2D and 2E clades reference
strains in PCV2a), 3/74 varied at position 131 (T to P, same
as 2A, 2C and 2E clade reference strains in PCV2a (white
boxes in Fig. 2); for PCV2a Cap amino acid sequences,
90.9% (10/11) PCV2a amino acid sequences had a T to N
substitution at position 134, which was the same as that in
1C clade reference strain in PCV2b genotype (shaded boxes
in Fig. 2). Interestingly, one of the 74 PCV2b sequences
investigated had a T to P substitution at position 64, which
is also present in the PCV2c reference strain (white box in
Fig. 2). In addition, there were other substitutions at
positions 28–34, 64, 118, 133–134 and 188 that were not
identified in any of the references strains (shaded but
unboxed in Fig. 2). Compared with the Cap sequence of
the chimeric PCV1–2a vaccine, the 11 PCV2a samples had
several variations such as at position 131 (T to P in 11/11
samples), 133 (A to V in 10/11 samples), 134 (T to D in 1/
11 sample, and T to N in 10/11 samples) and 136 (L to Q in
10/11 samples) (Fig. 2).
Prevalence of PCV1, PCV1-2a and PPV
PCV1 DNA was detected in 2.7% (45/1675) of the serum
samples and 2.0% (2/100) of the PCVAD cases. PCV1–2a
DNA was not identified in any of the tested samples. PPV
Table 1. Overall prevalence of PCV2a and PCV2b in the samples from healthy pigs (serum) regardless of vaccination status or from
PCVAD pigs (tissue)
Data are presented as number of positive samples, percentage (mean log10 PCV2 DNA copies ml
21±SEM).
Sample type No. PCV2a PCV2b
Serum 1 675 129, 7.7% (0.38±0.03)* 141, 8.4% (0.52±0.43)*
Tissue 100 13, 13.0% (1.21±0.32)D 65, 65.0% (6.47±0.52)D
Total 1 775 142, 8.0% (0.43±0.04) 206, 11.6% (0.86±0.06)
*,DDifferent superscripts within columns represent significant (P,0.05) differences in the mean amount of PCV2a or PCV2b DNA between sample
types.
Table 2. Prevalence of PCV2a and PCV2b in serum samples from vaccinated or non-vaccinated herds
Data are presented as number of positive samples, percentage (mean log10 PCV2 DNA copies ml
21±SEM).
Vaccination status No. PCV2a PCV2b
Vaccinated 1 177 0, 0% (0.00±0.00)* 117, 9.9% (0.64±0.06)*
Non-vaccinated 378 129, 34.1% (1.70±0.13)D 16, 4.2% (0.21±0.05)D
*,DDifferent superscripts within columns represent significant (P,0.05) differences in the mean amount of PCV2a or PCV2b DNA between samples
obtained from vaccinated and non-vaccinated herds.
Prevalence of PCV2 genotypes in vaccinated pigs
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DNA was detected in 1.0% (17/1675) of the serum samples
and in none of the PCVAD cases.
DISCUSSION
PCV2 vaccination has been demonstrated to be highly
efficient in inducing protective immunity against PCV2
infection and PCVAD under both experimental (Fort et al.,
2008; Opriessnig et al., 2008a; Shen et al., 2010b) and field
(Cline et al., 2008; Fachinger et al., 2008; Segale´s et al.,
2009) conditions. To the best of our knowledge, this is the
first epidemiological report investigating the prevalence of
PCV2 genotypes and clades after implementation of
widespread PCV2 vaccination programnes in the USA;
our data provide novel information on the distribution of
PCV2 genotypes and subtypes in the vaccinated pig
population, which is impossible to achieve under con-
trolled experimental studies. The aim of this study was not
to compare the efficacy of different commercial vaccines,
which were demonstrated to be equally effective in
previous experimental studies (Shen et al., 2010b). Since
many factors such as farm condition, age distribution,
vaccination protocol (time of vaccination, doses used) and
time of sample collection can influence results obtained
under field conditions, our data are not sufficient to draw
conclusions regarding possible differences in efficacy of
commercial PCV2 vaccines in the field. Moreover, the
serum samples and the tissue samples investigated in this
study all originated from different sites and geographical
variation could explain any differences in the results
obtained from the different sample types.
To our knowledge both the Ingelvac CircoFLEX and the
Circumvent PCV vaccines are based on PCV2a strains.
Since these two vaccines are subunit vaccines, based on
ORF2 protein expressed in a baculovirus vector, both
vaccines should be positive for PCV2a by the differential
PCV2a/PCV2b PCR which was confirmed in our lab (data
not shown). For Suvaxyn PCV, the PCV1–2a real-time
PCR assay used in this study contains special primers and a
probe for the chimeric region and this vaccine is also
positive by the differential PCR utilized in this study (data
not shown). Nevertheless, all the serum samples that
originated from confirmed vaccinated pigs were negative
for PCV2a DNA and potential detection of vaccine virus
can be ruled out. This result indicates that the current
commercial PCV2 vaccines are efficient in preventing
PCV2a viraemia. However, it is unexpected that the
diagnostic serum samples from known vaccinated pigs
had significantly higher PCV2b DNA loads than samples
derived from known non-vaccinated pigs. One explanation
could be that the currently available vaccines may be
relatively poor in cross-protecting against PCV2b infection
due to the PCV2a origin of the vaccine strains. This
hypothesis is in disagreement with a previous report, in
which a PCV2 subunit vaccine containing PCV2a Cap was
found to be equally effective in preventing viraemia,
decreasing nasal and faecal virus shedding caused by
PCV2a or PCV2b infection (Fort et al., 2008).
Alternatively, as the three vaccines available at the time
this study was done were licensed for usage as one dose
(Ingelvac CircoFLEX), two doses (Circumvent PCV) or
one or two dose application (Suvaxyn PCV) and since it is
unknown if the manufacturer’s instructions were followed,
this may also have impacted the results. The discrepancy
between the results obtained under experimental condi-
tions and the results obtained in the current USA field
investigation could be due to differences in circulating
PCV2 isolates, which are controlled strains under experi-
mental conditions compared with uncontrolled strains
with possible mutations under field conditions.
For the serum samples from non-vaccinated herds, 34.1%
(129/378) were positive for PCV2a; this prevalence was
lower than what was found in 2006 prior to PCV2
vaccination where over 82% of sera from 185 farms were
positive for PCV2 by PCR (Puvanendiran et al., 2011).
Furthermore, 3.1% (4/129) of the positive serum samples
from non-vaccinated herds had high PCV2 DNA loads of
more than 7 log10 PCV2 DNA copies ml
21 (data not
shown). Interestingly, Puvanendiran et al. (2011) found
that 7.2% (246/3424) of the PCV2 DNA-positive serum
samples had similarly high levels prior to PCV2 vaccina-
tion. Although differences in DNA extraction and PCR
assays could account for some of these differences, these
results suggest that the implementation of PCV2 vaccina-
tion on the USA pig population substantially reduced the
circulation of PCV2a in the population as a whole,
including herds that currently are not vaccinated.
In the PCVAD cases, PCV2 DNA was identified in 75% of
lung tissues. The lack of detection of PCV2 DNA in 25% of
the PCVAD cases in the current study could be explained
by testing only lung tissue and not pooling tissues or
including lymphoid tissues. In cases of enteric or systemic
PCVAD without a respiratory component, PCV2 DNA
would not necessarily be expected to be present in lung
tissues. Overall, we found a higher prevalence and higher
Table 3. Comparison of prevalence of PCV2b in serum
samples from farms with a history of PCV2 vaccination and
vaccine product information
Data are presented as number of positive samples, percentage (mean
log10 PCV2 DNA copies ml
21±SEM).
Vaccine Administration No. PCV2b*
Ingelvac
CircoFLEX
1 dose 184 32, 17.4%
(1.02±0.17)
Suvaxyn PCV 1 or 2 dose* 310 15, 4.8%
(0.35±0.09)
Circumvent PCV 2 doses 428 68, 15.9%
(1.01±0.12)
*Information on the actual dose used on a site or in a barn was not
available.
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DNA loads of PCV2b than PCV2a. This is consistent with
previous findings (Cheung et al., 2007). However, it is still
disputable as to whether the PCV2b genotype is more
virulent than the PCV2a genotype, since some investi-
gations found links between the PCV2b genotype and
occurrence of PCVAD (Chae & Choi, 2010; Cheung et al.,
2007; Grau-Roma et al., 2008; Timmusk et al., 2008) and
some did not (de Boisse´son et al., 2004; Martins Gomes de
Castro et al., 2007; Olvera et al., 2007). Under experimental
conditions, the virulence of PCV2a and PCV2b isolates is
not different in the conventional specific-pathogen-free pig
model (Opriessnig et al., 2008b); however, the virulence of
isolates within the same cluster differs (Opriessnig et al.,
2006, 2008b). Some studies indicate that PCV2a and
PCV2b co-infection or recombination may play a role in
PCV2 replication and pathogenesis. In a recent study, dual
heterologous PCV2a and PCV2b inoculation 7 days apart
induced severe clinical illness, but singular PCV2a or
PCV2b appeared to be of equivalent virulence (Harding et
al., 2010). Another study performed on tissues from
PCVAD cases in Switzerland revealed that both PCV2a
and PCV2b were equally present in PCV2 pre-epizootic-
and post-epizootic-infected piglets, and superinfections
and co-replication of the two major PCV2 genotypes
(PCV2a and PCV2b) were observed in vivo (Khaiseb et al.,
2011). In addition, two recombinant mutants of PCV2
with PCV2b ORF1 and PCV2a ORF2 were shown to have
enhanced replication efficiencies compared with the
parental strains (Guo et al., 2011). All these studies suggest
PCV2a and PCV2b may interact with each other during
infection. It is notable that in the present study even
though PCV2a was not the prevalent genotype in PCVAD,
PCV2 1B 
clade
PCV2 2E 
clade
PCV2a
genotype
PCV2b
genotype
 40 (JN575674) (1)
 PCV21B AY678532
 16 (JN575653) (1)
 35 (JN575670) (2)
 04 (JN575641) ( 1)
 66 (JN575695) (3)
 14 (JN575651) (3)
 13 (JN575650) (3)
 03 (JN575640) (52)
 92 (JN575719) (1)
 38 (JN575672) (1)
 88 (JN575716) (1)
 34 (JN575669) (3)
 33 (JN575668) (1)
 91(JN575718) (1)
 PCV21A AY122275
 PCV2b ref AF055394
 PCV2c ref EU148503
 PCV21C AY510375
 PCV22B AY146991
 PCV2a ref AF055392
 08 (JN575645) (1)
 PCV22E AF264039
 27 (JN575662) (9)
 76 (JN575705) (1)
 PCV1-2a AF264042
 PCV22D AF264043
 PCV22A  AF117753
 PCV22C AF20130869
53
29
37
34
5
17
31
90
43
72
50
65
29
31
22
47
35
3
0.005
Fig. 1. Phylogenetic analysis of the representative partial PCV2 ORF2 sequences (9–563 nt) obtained in this study and 11
PCV2 clade (1A–1C and 2A–2D) and genotype (2a, 2b and 2c) and PCV1–2a vaccine reference sequences. The
phylogenetic tree was constructed by the NJ method. Significant bootstrap values are indicated as a percentage for 1000
replicates. The reference sequences for PCV2 clades related to the sequences in this study are indicated in the boxes.
Sequences obtained in the present study are presented as follows: sequence ID (GenBank accession number) (numbers of
sequences with distances of ,0.005 in pairwise comparisons).
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it was still associated with 13.0% of the cases and the co-
existence of PCV2a with PCV2b in the same pig may
facilitate the interaction and recombination of PCV2a and
PCV2b genotypes in the USA field.
To further characterize the prevalence of the PCV2 strains
in the field, we determined the main PCV2 clades (or
subgroups) by phylogenetic analysis of partial ORF2
sequences with different clade reference sequences reported
previously (Olvera et al., 2007). We found that all the
PCV2a nucleotide sequences belonged to the 2E clade and
all the PCV2b sequences belonged to the 1B clade. In a
previous report on genotypic analysis of PCV2 strains in
the swine herds of the USA, the PCV2a strains were
included in 2D and 2E clades, and PCV2b in 1A clade
(Cheung et al., 2007). It should be pointed out that the 1B
clade classification in our study is related to the reference
strain we selected. Since there were no amino acid
differences in Cap between 1A and 1B clades (Olvera
et al., 2007), the 1B clade can be considered the same as 1A
or 1A/B. In contrast to the USA, 1A and 1C clades for
PCV2b, 2D and 2E for PCV2a have been reported in
Republic of Korea (Chae & Choi, 2010); 1 A/B and 1C for
PCV2b was reported in Thailand (Jantafong et al., 2011).
Up to now, the possible relationship between pathogenicity
and PCV2 clades is unclear.
Cap serves as a protective antigen (Blanchard et al., 2003;
Fenaux et al., 2004; Shen et al., 2008) and serological
marker (Mahe´ et al., 2000; Truong et al., 2001) for PCV2.
Distinct amino acid sequences have been suggested as
signature motifs for PCV2a and PCV2b genotypes (Cheung
et al., 2007). In the present study, the putative amino acid
sequences revealed that 100% (74/74) of the PCV2b
contained the signature motif of SNPRSV, and 90.9% (10/
11) of the PCV2a contained the signature motif of TNKISI
at positions 86–90. However, 9.1% (1/11) of PCV2a had
PCV2b substitution (T to S) at position 86 in the signature
motif. In addition, we found PCV2a amino acid substitu-
tions at positions 30, 76 and 131 in PCV2b Cap, and
PCV2b amino acid substitutions at position 134 in PCV2a.
These substitutions may be caused by possible recombina-
tion between PCV2a and PCV2b or mutations. Position 30
was located in one of the two dominant regions (22–41 and
71–86) (Wen et al., 2005), and positions 76, 131 and 134
were located in the variant regions (Larochelle et al., 2002;
Wang et al., 2009) as well as antigenic domains
(Lekcharoensuk et al., 2004; Mahe´ et al., 2000; Truong
et al., 2001). Since PCV2 is subject to selective pressure
exerted by the pre-existing acquired immunity in the popu-
lation, it can be deduced that these selected amino acid
substitutions between PCV2a and PCV2b are favourable
for viral evasion from the immunity elicited by the
currently used vaccines. In a previous study, a transition
of amino acid from T to P at position 151 of Cap was
found to be due to positive selection (Firth et al., 2009);
however, we did not identify mutations at this position in
our study. Previous studies also suggest that the immu-
noreactive regions of Cap of PCV2 are potential candidate
regions involved in the emergence of novel PCV2 variants
(Larochelle et al., 2002; Wellenberg et al., 2000; Wen et al.,
2005).
In the present study, PCV1 DNA was detected in 2.7% of
the serum samples and 2.0% of the PCVAD cases. This
result is consistent with an investigation in USA finishing
swine herds in 2006 prior to PCV2 vaccination where only
2.4% of sera from 185 farms were positive for PCV1 by
PCR (Puvanendiran et al., 2011). For detection of possible
PCV1 and PCV2 recombination and vaccine derivatives,
we utilized a real-time PCR method that is capable of
detecting chimeric PCV1–2a or PCV1–2b DNA containing
PCV1 ORF1 and PCV2 ORF2 that originated from either
PCV2a or PCV2b. PCV1–2a DNA was not identified in any
of the samples, suggesting that this kind of recombination
between PCV1 ORF1 and PCV2 ORF2 was rare or
undetectable in the USA field. In 2010, PCV1–2a contain-
ing the ORF1 of PCV1 and the ORF2 of PCV2a was
identified in Canada with a prevalence of 2.5% (Gagnon
et al., 2010). The origin of PCV1–2a was thought to be the
result of natural genetic recombination between PCV1 and
PCV2a or a virus originating from a chimeric inactivated
vaccine strain (Gagnon et al., 2010). In the present study,
we had 310 serum samples confirmed to be from pigs (with
ages of 10–23 weeks) vaccinated with an inactivated
chimeric PCV2 vaccine (Suvaxyn PCV). The negative
results for PCV1–2a chimeric DNA on these serum samples
and on all other serum samples collected from non-
vaccinated farms or farms that used a different PCV2
vaccine in addition to the negative results for PCV1–2a
chimeric DNA on all tissue samples collected from PCVAD
pigs suggested that this vaccine is not likely to cause
emergence of a PCV1–2a recombinant virus in the USA.
However, it is difficult to compare the absence of PCV1–2a
in the current survey to the presence of PCV1–2a reported
in Canada (Gagnon et al., 2010), due to the differences in
pig ages, sample types and laboratory methods between the
two studies and different batches of the Suvaxyn PCV
vaccine used in these two countries.
PCV2 Cap is capable of inducing PCV2 neutralizing
antibody (McNeilly et al., 2001; Shen et al., 2008; Zhou
et al., 2005). The antigenetic diversity of PCV2 Cap was
demonstrated by differentiation of different PCV2 strains
Fig. 2. Amino acid sequence alignment of the representative partial putative Cap (4–188 aa) obtained in this study and that
from and 11 PCV2 clade (1A–1C and 2A–2D) and genotype (2a, 2b and 2c) and PCV1–2a vaccine reference sequences.
White boxes indicate PCV2a- or PCV2c-related amino acid substitutions in PCV2b; shaded boxes indicate PCV2b-related
amino acid substitutions in PCV2a; shaded but unboxed areas indicate unrecognized amino acid substitutions; the stop codon
is presented as asterisk (*).
Prevalence of PCV2 genotypes in vaccinated pigs
http://vir.sgmjournals.org 1351
by certain mAbs (Lefebvre et al., 2008; Shang et al., 2009).
In challenge models, the severity of PCV2-associated
lesions was reduced in pigs with prior exposure to an
isolate from the heterologous cluster in comparison with
singly inoculated pigs (Opriessnig et al., 2008b, 2010). The
live-attenuated chimeric PCV2 vaccine based on subtype
PCV2a was found to be effective in reducing PCV2b
viraemia (Opriessnig et al., 2011a; Shen et al., 2010b). And
vice versa, the live-attenuated chimeric PCV2b vaccine is
effective in producing protective immunity against PCV2a
infection (Beach et al., 2010; Opriessnig et al., 2011b). All
these results suggest that cross-protection between PCV2a
and PCV2b exists. However, the present study indicated
that the vaccinated herds still had higher level of PCV2b
viraemia than the non-vaccinated herds. This observation
may suggest a need for a new generation of PCV2 vaccines
based on the PCV2b genotype or both PCV2a and 2b. In
addition, we detected exclusive 1B and 2E clades in this
study. Based on this, we speculate that introducing vaccines
based on the strains and the same clade will increase the
vaccine efficacy against PCV2a or PCV2b infection. The
effect of amino acid substations in Cap on the pathogeni-
city and antigenicity of the virus is still unclear. Therefore,
further studies need to be performed to better understand
the importance of these observations.
METHODS
Samples. A total of 1675 serum samples from 61 USA sites (with one
to five barns on each site and a total of 105 barns) located in seven
States (IA, IL, IN, MO, NC, ND and OH) were obtained in groups of
5–97 samples for each barn (mean: 16.2 samples, CI: 13.5, 19.1).
These samples were either selected as a convenience sample based on
availability through the Iowa State University (ISU) Veterinary
Diagnostic Laboratory (VDL) or submitted directly by participating
veterinarians for the purpose of this study. The age of the pigs ranged
from 1 to 26 weeks for 69.4% (1162/1675) of the serum samples in
addition to 26.1% (438/1675) samples with no detailed age
information; only 4.5% (75/1675) samples were collected from pigs
of 1–9 or 27–30 weeks of age.
If PCV2 vaccination and product information was available, this was
included in the investigation. The PCV2 vaccines utilized in the USA
at and before the time of sample collections included Suvaxyn PCV
(now reformulated and available as Fostera PCV; Pfizer Animal
Health, Inc.), Ingelvac CircoFLEX (Boehringer Ingelheim Vetmedica,
Inc.) and Circumvent PCV (Merck Animal Health, Inc.). While
Suvaxyn PCV can be administered in a one (2 ml) or two dose (1 ml
twice) fashion, Ingelvac CircoFLEX is licensed for one dose
administration (1 ml) and Circumvent PCV is licensed for two dose
administration (2 ml twice) in the USA. All of these vaccines are
licensed for usage in healthy pigs 3 weeks and older and have been
available in the USA since 2006. The age of vaccinated pigs from
which serum samples were collected ranged from 12 to 25 weeks
(mean±SEM, 18.1±0.2) for Ingelvac CircoFLEX and 10–23 weeks for
both Suvaxyn PCV (mean±SEM, 17.2±0.2) and Circumvent PCV
(mean±SEM, 11.9±0.2). In addition to the serum samples, 100 lung
tissue samples from 75 sites (1–5 samples for each farm) located in 13
USA states (CO, IA, IL, IN, MD, MI, MN, MO, NC, ND, OK, UT and
WI) were obtained through the ISU-VDL from pigs diagnosed with
PCVAD based on histopathology using general requirements such as
microscopic lesions associated with high amounts of PCV2 antigen as
determined by immunohistochemistry. The age of the pigs ranged
from 5 to 23 weeks (11.9±0.6) for tissue samples, with 33.0% (33/
100) of the pigs having no available age information. All the serum
and tissue samples were collected between November 2010 and June
2011.
DNA extraction. DNA was extracted from the serum samples or
tissue homogenates using an automated extraction machine (King
Fisher Flex 96 Ambion; Thermo Scientific) and the MagMAX-96 viral
isolation kit (Ambion) according to the manufacturer’s instructions.
Serum samples were subjected to extraction directly, whereas tissue
samples were processed prior to extraction as follows: tissue samples
were mechanically homogenized in sterile Earle’s medium (Sigma-
Aldrich) at a ratio of 1 g to 3 ml by using a stomacher (Seward
Stomacher 80; Seward) for 120 s. The homogenates were centrifuged
at 3200 g for 30 min at 4 uC and the supernatant was transferred into
5 ml tubes. The tubes were stored at 220 uC until the day of the
extraction.
Quantitative differential real-time PCR for PCV2a and PCV2b.
Quantitative differential PCR for PCV2a and PCV2b was performed
in a multiplex manner using the same primers and probe as described
previously (Shen et al., 2010a). Probes for PCV2a and PCV2b were
synthesized and labelled with CAL Fluor Orange 560 and Quasar 670
(Biosearch Technologies), respectively. The multiplex real-time PCR
consisted of a total volume of 25 ml containing 12.5 ml of the
commercially available master mix (TaqMan Universal PCR master
mix; PE Applied Biosystems), 2.5 ml extracted sample DNA, 1 ml
(0.4 mM) of each of the two primers, 0.5 ml (0.2 mM) of each of the
two probes and 7 ml of DNase/RNase-free water. The reactions were
carried out in a 7500 Fast Real-Time PCR system (ABI) under the
following conditions: 50 uC for 2 min, 95 uC for 10 min, followed by
40 cycles of 95 uC for 15 s, and 60 uC for 1 min. The results were
expressed as the number of PCV2 genomic copies ml21. Serial
dilutions of PCV2a and PCV2b genomic DNA clones were used to
generate standard curves that were demonstrated to have a correlation
coefficient of more than 0.90. The sensitivity of the differential PCR
for PCV2a and PCV2b was 1.66103 PCV2 DNA copies ml21 (four
copies per reaction) for both PCV2a and PCV2b. There were no
cross-reactions with PCV1, PCV1–2a and between PCV2a and
PCV2b.
Real-time PCR for PCV1, chimeric PCV1–2a and PPV. PCV1
(Shen et al., 2011), PCV1–2a (Shen et al., 2010b) and PPV (Shen et
al., 2010b) real-time PCR assays were performed as described
previously. PCV1 real-time PCR was performed in a non-quantitative
manner with a correlation coefficient of more than 0.90 in serial
dilutions of PCV1 viral genomic DNA; there were no cross-reactions
with PCV2a, PCV2b and PCV1–2a. Five progressive 10-fold dilutions
of a PCV1–2a chimeric DNA clone were used to generate a standard
curve, which had a correlation coefficient of more than 0.99. The
sensitivity of the PCV1–2a real-time PCR is 8.136104 copies ml21
(204 copies per reaction); the specificity test revealed that this assay
had no cross-reactions with PCV1, PCV2a, PCV2b or PPV. Serial
dilutions of a recombinant plasmid containing the PPV VP2 gene
were used for obtaining a standard curve that had a correlation
coefficient of more than 0.99. The specificity of the PPV PCR was
evaluated and there were no cross-reactions with PCV1 and PCV2,
and the detection limit of this assay was found to be 103 copies ml21
(2.5 copies per reaction).
PCV2 sequencing. Part (667 bp) of the PCV2 ORF2 was amplified
with P2ORF2F (59-CTCTGAATTGTACATACATGGTTACACGGA-
39) and P2ORF2R (59-ATGACGTATCCAAGGAGGCGTTA-39) as
forward and reverse primers, respectively (Gagnon et al., 2010). The
PCR was performed in a GeneAmp PCR system 9700 (Applied
Biosystems) in 25 ml mixtures containing 1.25 U (0.25 ml) Taq DNA
H.-G. Shen, P. G. Halbur and T. Opriessnig
1352 Journal of General Virology 93
polymerase (Invitrogen), 0.2 mM dNTP, 0.4 mM each of the primers,
1.5 mM MgCl2 and 4 ml DNA extract. The cycling conditions were
5 min at 95 uC, followed by 35 cycles of 40 s at 95 uC, 40 s at 55 uC
and 1 min at 72 uC and finally extension at 72 uC for 7 min. The
amplified PCR products were separated by gel electrophoresis on 1%
agarose gel (Amresco) and visualized by UV irradiation after
ethidium bromide staining of the gel. The specific products were
sequenced at the ISU DNA facility, Ames, Iowa.
Phylogenetic analysis. Sequences of 555 nt (9–563 nt) from PCV2
ORF2 were aligned by the CLUSTAL W method available in the MEGA
5.05 software (http://www.megasoftware.net/). Distance computation
was expressed as the number of base substitutions per site between
sequences by the Maximum Composite Likelihood model in MEGA
5.05. Nucleotide sequences with distances of less than 0.005 in
pairwise comparisons (which means nearly identical or identical
sequences, and limited to a maximum of 3 nt differences and one
putative amino acid difference) were represented as one sequence and
used in phylogenetic analysis. Sequences were aligned with the
PCV2a, 2b and 2c genotype references (Segale´s et al., 2008) and 1A to
1C (in PCV2b genotype) and 2A to 2E (in PCV2a genotype) clade
references (Olvera et al., 2007). The nucleotide distance of sequences
was evaluated by a neighbour-joining (NJ) tree using MEGA 5.05
(Kumar et al., 2001). Confidence in the NJ tree was estimated by 1000
bootstrap replicates.
Statistical analysis. Statistical analysis of the data was performed by
one-way analysis of variance (ANOVA) using the SAS software
version 9.2.0 (SAS Institute). Real-time PCR results (copies ml21 of
serum) were log10 transformed prior to statistical analysis. For log-
transformed real-time PCR results, linear mixed models were used for
analysis. Site and barn (nested within site) were used as random
effects and sample type (serum and tissue), vaccine status (vaccinated
and non-vaccinated) or vaccine product (Ingelvac CircoFLEX,
Suvaxyn PCV and Circumvent PCV) were used as fixed effect. For
binary prevalence analyses, mixed effect logistic regression models
were used. A P-value of less than 0.05 was set as a statistically
significant level throughout this study.
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